Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial
Article
Overview
publication date
- January 1, 2015
published in
- The Lancet Oncology Journal
Identity
Scopus Document Identifier
- 84924942665
Digital Object Identifier (DOI)
- 10.1016/S1470-2045(15)70076-8